We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Antiplatelet Therapy
MedXY News
EnglishTag

Antiplatelet Therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial
Internal Medicinestroke preventionAntiplatelet Therapy

Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial

By MedXY|Aug 18, 2026

The STATICH trial assessed safety and efficacy of antiplatelet therapy after intracerebral hemorrhage, revealing increased hemorrhagic risk but fewer ischemic events among treated patients, highlighting ongoing clinical dilemmas.

Reevaluating Acute Treatment Strategies for Spontaneous Spinal Cord Infarction: Insights from a Propensity Score-Matched Study
NeurologyThrombolysisstroke
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Reevaluating Acute Treatment Strategies for Spontaneous Spinal Cord Infarction: Insights from a Propensity Score-Matched Study

By MedXY|Aug 18, 2026

This retrospective analysis reveals that standard antiplatelet therapy may reduce mortality compared to thrombolysis in acute spontaneous spinal cord infarction, highlighting the need for cautious therapeutic decisions pending stronger evid

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative
CardiologyanticoagulationAntiplatelet Therapy

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

By MedXY|Jun 25, 2026

A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation
CardiologyAntiplatelet Therapyclopidogrel

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation

By MedXY|May 12, 2026

This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations
Diabetes & EndocrinologyAntiplatelet TherapyCYP2C19

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations

By MedXY|Jan 22, 2026

A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resis

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial
CardiologyAntiplatelet TherapyCardiology

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

By MedXY|Jan 17, 2026

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS
Cardiologyacute coronary syndromeAntiplatelet Therapy

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

By MedXY|Jan 2, 2026

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombo

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis
Cardiologyacute coronary syndromeAntiplatelet Therapy

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY|Dec 18, 2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis
CardiologyAntiplatelet TherapyAspirin

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

By MedXY|Oct 11, 2025

This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial
CardiologyAntiplatelet Therapybleeding risk

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

By MedXY|Oct 9, 2025

The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increa

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up
CardiologyAntiplatelet TherapyAspirin

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY|Oct 9, 2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Antiplatelet vs Anticoagulant Therapy in Embolic Stroke of Undetermined Source: Insights from a Large Multicenter Cohort Study
Clinical UpdatesanticoagulationAntiplatelet Therapy

Antiplatelet vs Anticoagulant Therapy in Embolic Stroke of Undetermined Source: Insights from a Large Multicenter Cohort Study

By MedXY|Oct 3, 2025

This study found no overall advantage of anticoagulation over antiplatelet therapy in ESUS patients but identified a potential benefit of anticoagulation in those with left ventricular injury.

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial
CardiologyAbelacimabAntiplatelet Therapy

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY|Oct 3, 2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities